Coherus Accounts Payable from 2010 to 2025

CHRS Stock  USD 0.96  0.01  1.05%   
Coherus BioSciences Accounts Payable yearly trend continues to be comparatively stable with very little volatility. Accounts Payable will likely drop to about 19.6 M in 2025. Accounts Payable is the amount Coherus BioSciences owes to suppliers or vendors for products or services received but not yet paid for. It represents Coherus BioSciences' short-term liabilities. View All Fundamentals
 
Accounts Payable  
First Reported
2012-12-31
Previous Quarter
21.9 M
Current Value
28.5 M
Quarterly Volatility
12.5 M
 
Yuan Drop
 
Covid
Check Coherus BioSciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Coherus BioSciences' main balance sheet or income statement drivers, such as Depreciation And Amortization of 5.5 M, Interest Expense of 16.9 M or Selling General Administrative of 106.6 M, as well as many indicators such as Price To Sales Ratio of 0.56, Dividend Yield of 0.0 or Days Sales Outstanding of 93.4. Coherus financial statements analysis is a perfect complement when working with Coherus BioSciences Valuation or Volatility modules.
  
Check out the analysis of Coherus BioSciences Correlation against competitors.
For more information on how to buy Coherus Stock please use our How to Invest in Coherus BioSciences guide.

Latest Coherus BioSciences' Accounts Payable Growth Pattern

Below is the plot of the Accounts Payable of Coherus BioSciences over the last few years. An accounting item on the balance sheet that represents Coherus BioSciences obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Coherus BioSciences are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. It is the amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities. Coherus BioSciences' Accounts Payable historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Coherus BioSciences' overall financial position and show how it may be relating to other accounts over time.
Accounts Payable10 Years Trend
Slightly volatile
   Accounts Payable   
       Timeline  

Coherus Accounts Payable Regression Statistics

Arithmetic Mean16,215,893
Geometric Mean12,768,673
Coefficient Of Variation61.23
Mean Deviation7,759,492
Median15,714,000
Standard Deviation9,929,355
Sample Variance98.6T
Range31.5M
R-Value0.67
Mean Square Error58T
R-Squared0.45
Significance0
Slope1,400,074
Total Sum of Squares1478.9T

Coherus Accounts Payable History

202519.6 M
202428.5 M
202335.2 M
202211.5 M
202116.2 M
202015.2 M
201926 M

About Coherus BioSciences Financial Statements

Coherus BioSciences shareholders use historical fundamental indicators, such as Accounts Payable, to determine how well the company is positioned to perform in the future. Although Coherus BioSciences investors may analyze each financial statement separately, they are all interrelated. The changes in Coherus BioSciences' assets and liabilities, for example, are also reflected in the revenues and expenses on on Coherus BioSciences' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Accounts Payable28.5 M19.6 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Coherus Stock Analysis

When running Coherus BioSciences' price analysis, check to measure Coherus BioSciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Coherus BioSciences is operating at the current time. Most of Coherus BioSciences' value examination focuses on studying past and present price action to predict the probability of Coherus BioSciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Coherus BioSciences' price. Additionally, you may evaluate how the addition of Coherus BioSciences to your portfolios can decrease your overall portfolio volatility.